written on 12.03.2014

CA panel shivs Gilead's Sovaldi on price, suggests focusing it on sickest hep C patients


Payers are growing increasingly balky at the price Gilead Sciences slapped on its breakthrough hepatitis C pill Sovaldi. An expert panel in California that assesses new treatments voted Sovaldi a "low value" treatment–not because it doesn't work well enough, but because of its $1,000-a-pill price tag.